IRVINE, Calif., Jan. 31, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the publication of favorable clinical results for the Nellix technology for the endovascular repair of abdominal aortic aneurysm (EVAR). The peer-reviewed article reported initial results from the international multicenter clinical trial, with successful aneurysm exclusion in all patients, and no late aneurysm or device-related adverse events or secondary procedures.
Lead author and scientific advisor Carlos E. Donayre, MD (Harbor-UCLA Medical Center, Torrance, CA) commented, "The Nellix technology was designed to address the limitations of currently available EVAR devices and to expand the therapy to more patients. By filling the aneurysm sac, the Nellix device may reduce the incidence of endoleaks, secondary interventions and the need for annual CT scan follow-up. We are encouraged by these promising results, and look forward to the availability of broader experience in the near future."
The publication, entitled "Initial clinical experience with a sac anchoring endoprosthesis for aortic aneurysm repair," was published in the February issue of the Journal of Vascular Surgery (JVS). The study examined the initial and one year outcomes of 21 patients treated at four international centers. An independent core laboratory analyzed preoperative and post-procedural computed tomography scans to determine aneurysm exclusion and device stability over time.
John McDermott, President and Chief Executive Officer said, "We believe the Nellix technology represents the next generation in endovascular repair of abdominal aortic aneurysms. Since completing the acquisition in December 2010, we are delighted that initial results of the international trial are now published by a peer review journal and we look forward to providing the clinical community with updates as more data is available. In addition to Nellix, our Ventana™ fenestrated stent graft and AFX system continue to advance on schedule. We believe this robust new product pipeline will enable us to expand the EVAR market and continue to capture market share."
About Journal of Vascular Surgery
Journal of Vascular Surgery provides vascular, cardiothoracic, and general surgeons with the most recent information in vascular surgery. Original, peer-reviewed articles cover clinical and experimental studies, noninvasive diagnostic techniques, processes and vascular substitutes, microvascular surgical techniques, angiography, and endovascular management. Special issues publish papers presented at the annual meeting of the Society for Vascular Surgery. Journal of Vascular Surgery ranks 14th of 166 journals in Surgery and 14th of 60 journals in the Peripheral Vascular Disease categories on the 2009 Journal Citation Reports®, published by Thomson Reuters, and has an Impact Factor of 3.517.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.
Except for historical information contained herein, this news release contains forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the success of sales efforts for the Powerlink System and related new products, product research and development efforts, and other economic, business, competitive and regulatory factors. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other filings with
the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.
The Ruth Group
John McDermott, CEO
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020
SOURCE Endologix, Inc.